Genedrive PLC Update on US Department of Defense Programme
January 16 2017 - 2:00AM
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
16 January 2017
For release: 16 January 2017
genedrive plc Reports Delivery of Genedrive(R) Units and Assays
to the US Department of Defense in Programme to Develop a Handheld
Biohazard Identifier
genedrive plc, a Manchester-based diagnostics company, today
announces it has supplied Genedrive(R) units and assays to the
United States Department of Defense (DoD) for field trials as part
its $7.8m development programme for a handheld device to allow for
the detection of biohazards - such as biological warfare
agents.
Good progress has been made in the second, EUR2.9m, phase of the
programme first announced in March 2016, and the supply of units
for field trials follows further development work and
validation.
Genedrive(R) is a small, portable, versatile system which can
rapidly analyse DNA without the need for sophisticated laboratory
equipment. In addition to the DoD programme, Genedrive(R) is being
used to test for TB in India and assays are under development for
Hepatitis C (HCV) and other infectious diseases. Genedrive(R) is
also being developed for use in aquaculture to test for diseases in
commercial fisheries.
The aim of the DoD programme has been to develop a smaller,
lighter, more portable system that can detect multiple different
agents with a single cartridge to allow more units to be deployed
and more tests to be done. This is against a backdrop of military
personnel being expected to carry ever increasing amounts of
equipment and the logistical and cost implications of that
demand.
"The goal of the programme is to use the key characteristics of
Genedrive(R), its portability and flexibility, to develop a device
and test combination that can potentially be widely deployed in the
field both for homeland protection and across the world. Our
cartridges detect multiple agents but are small enough to fit in a
pocket. The device weighs less than one kilogram and is relatively
low cost meaning multiple units could be bought and put into use,"
said David Budd, Chief Executive Officer of genedrive plc. "We are
now working with the DoD on tests in the field to confirm the
results we've seen so far on Genedrive(R)'s robustness and the
accuracy of the tests".
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel
+44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF test have been
launched in India and a Genedrive(R) HCV test has been successfully
assessed by the Institut Pasteur, Paris.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGMGMMFKNGNZZ
(END) Dow Jones Newswires
January 16, 2017 02:00 ET (07:00 GMT)
Epistem (LSE:EHP)
Historical Stock Chart
From Apr 2024 to May 2024
Epistem (LSE:EHP)
Historical Stock Chart
From May 2023 to May 2024